Baxter splashes out $325m on biomaterials firm Synovis
This article was originally published in Clinica
Executive Summary
Baxter International has boosted its regenerative and biosurgical offering by agreeing to acquire Synovis Life Technologies, which develops products for soft tissue repair during surgery. The deal is worth $28 per share, which equates to $325m of equity or around $260m after adjusting for net cash.